Fatty Acid Synthase–Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD

Yufeng Hu,Wenzhi He,Yongping Huang,Hui Xiang,Juan Guo,Yan Che,Xu Cheng,Fengjiao Hu,Manli Hu,Tengfei Ma,Jie Yu,Han Tian,Song Tian,Yan‐Xiao Ji,Peng Zhang,Zhi‐Gang She,Xiao‐Jing Zhang,Zan Huang,Juan Yang,Hongliang Li

DOI: https://doi.org/10.1002/hep.32045

IF: 17.298

2021-09-21

Hepatology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background &amp; Aims</h3><p>Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease without any FDA-approved pharmacological intervention in clinic. Fatty acid synthase (FASN) is one of the most attractive targets for NAFLD treatment because of its robust rate-limiting capacity to control hepatic <i>de novo</i> lipogenesis (DNL). However, the regulatory mechanisms of FASN in NAFLD and potential therapeutic strategies targeting FASN remain largely unknown. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods &amp; Results</h3><p>Through a systematic interactomics analysis of FASN-complex proteins, we screened and identified sorting nexin 8 (SNX8) as a new binding partner of FASN. SNX8 directly bound to FASN and promoted FASN ubiquitination and subsequent proteasomal degradation. We further demonstrated that SNX8 mediated FASN protein degradation by recruiting the E3 ligase tripartite motif containing 28 (TRIM28) and enhancing the TRIM28-FASN interaction. Notably, <i>Snx8</i> interference in hepatocytes significantly deteriorated lipid accumulation <i>in vitro</i>, whereas SNX8 overexpression markedly blocked hepatocyte lipid deposition. Furthermore, the aggravative effect of <i>Snx8</i> deletion on NAFLD was validated <i>in vivo</i>, as hepatic steatosis and lipogenic pathways in the liver were significantly exacerbated in <i>Snx8</i>-knockout mice compared to wild-type controls. Consistently, hepatocyte-specific overexpression of <i>Snx8 in vivo</i> markedly suppressed HFHC-induced hepatic steatosis. Notably, the protective effect of SNX8 against NAFLD was largely dependent on FASN suppression. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These data indicate that SNX8 is a key suppressor of NAFLD that promotes FASN proteasomal degradation. Targeting the SNX8-FASN axis is a promising novel strategy for NAFLD prevention and treatment.</p></section>

gastroenterology & hepatology